Abstract:CRISPR/Cas9 and single-stranded DNA oligonucleotides (ssODNs) have been used to direct the repair of a single base mutation in human genes. Here, we examine a method designed to increase the precision of RNA guided genome editing in human cells by utilizing a CRISPR/Cas9 ribonucleoprotein (RNP) complex to initiate DNA cleavage. The RNP is assembled in vitro and induces a double stranded break at a specific site surrounding the mutant base designated for correction by the ssODN. We use an integrated mutant eGFP gene, bearing a single base change rendering the expressed protein nonfunctional, as a single copy target in HCT 116 cells. We observe significant gene correction activity of the mutant base, promoted by the RNP and single-stranded DNA oligonucleotide with validation through genotypic and phenotypic readout. We demonstrate that all individual components must be present to obtain successful gene editing. Importantly, we examine the genotype of individually sorted corrected and uncorrected clonally expanded cell populations for the mutagenic footprint left by the action of these gene editing tools. While the DNA sequence of the corrected population is exact with no adjacent sequence modification, the uncorrected population exhibits heterogeneous mutagenicity with a wide variety of deletions and insertions surrounding the target site. We designate this type of DNA aberration as on-site mutagenicity. Analyses of two clonal populations bearing specific DNA insertions surrounding the target site, indicate that point mutation repair has occurred at the level of the gene. The phenotype, however, is not rescued because a section of the single-stranded oligonucleotide has been inserted altering the reading frame and generating truncated proteins. These data illustrate the importance of analysing mutagenicity in uncorrected cells. Our results also form the basis of a simple model for point mutation repair directed by a short single-stranded DNA oligonucleotides and CRISPR/Cas9 ribonucleoprotein complex.

Gene Correction of Point Mutations Using PolyPurine Reverse Hoogsteen Hairpins Technology

Efficient Repair of Human Genetic Defect by CRISPR/Cas9-mediated Interlocus Gene Conversion

Nucleic acids therapeutics using PolyPurine Reverse Hoogsteen hairpins

Correction of a pathogenic gene mutation in human embryos

Insertional Mutagenesis by CRISPR/Cas9 Ribonucleoprotein Gene Editing in Cells Targeted for Point Mutation Repair Directed by Short Single-Stranded DNA Oligonucleotides

Non-viral Delivery of CRISPR–Cas9 Complexes for Targeted Gene Editing Via a Polymer Delivery System

CRISPR-Cas12a System With Synergistic Phage Recombination Proteins for Multiplex Precision Editing in Human Cells

Search-and-replace genome editing without double-strand breaks or donor DNA

Peptide Nucleic Acids and Gene Editing: Perspectives on Structure and Repair

Improved specificity and efficacy of base-editing therapies with hybrid guide RNAs

Oligonucleotide-directed gene-editing technology: mechanisms and future prospects

Efficient Generation and Correction of Mutations in Human iPS Cells Utilizing mRNAs of CRISPR Base Editors and Prime Editors

Precise CRISPR-Cas–mediated gene repair with minimal off-target and unintended on-target mutations in human hematopoietic stem cells

Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair

DNA and RNA base editors can correct the majority of pathogenic single nucleotide variants

Harnessing RNA-based DNA repair pathways for targeted gene editing

Targeted Gene Insertion: The Cutting Edge of CRISPR Drug Development with Hemophilia as a Highlight

Haplotype editing with CRISPR/Cas9 as a therapeutic approach for dominant-negative missense mutations in

Next generation triplex-forming PNAs for site-specific genome editing of the F508del CFTR mutation

ZFN-Mediated In Vivo Genome Editing Corrects Murine Hurler Syndrome

Enhanced homology-directed repair for highly efficient gene editing in hematopoietic stem/progenitor cells